Influenza Therapeutics Market Growth Analysis And Trends 2023-2030

Global Influenza Therapeutics Market Sees Rapid Advancements in Clinical Trials and Growing Concerns Over Influenza-Related Deaths

Influenza, a prevalent flu-like illness caused by the influenza virus, continues to pose a significant public health concern, with symptoms that include chills, fever, and more. The primary mode of transmission is through tiny airborne droplets from the coughs or sneezes of infected individuals. To combat this ongoing health threat, the Centers for Disease Control and Prevention (CDC) emphasizes the importance of annual flu vaccinations as a preventative measure against serious health risks and potential fatalities.

Annual outbreaks of influenza remain a pressing issue, with many individuals resorting to over-the-counter medications, including anti-viral and anti-microbial drugs, to manage their flu-like symptoms. According to the World Health Organization (WHO), the global influenza attack rate stands at 20% to 30% among children and approximately 10% in adults, leading to a staggering annual death toll ranging from 290,000 to 650,000.

Know More: Download Sample

Influenza Therapeutics Market Dynamics: Drivers & Restraints

Clinical trials play a pivotal role in advancing the development of vaccines that enhance safety and efficacy while minimizing adverse effects. For instance, Mahidol University and the Government Pharmaceutical Organization have initiated phase 3 clinical trials to evaluate the immunogenicity and safety of Tri Fluvac, a seasonal trivalent inactivated split virion influenza vaccine. Notably, the trials began on August 3, 2020, and are expected to conclude on December 31, 2023.

The National Institute of Allergy and Infectious Diseases (NIAID) is also contributing to influenza vaccine research by conducting a phase 1 clinical trial to assess the safety and tolerability of the Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults. This initiative commenced on August 9, 2023, and is scheduled for completion on December 16, 2024.

Nanjing Zenshine Pharmaceuticals has undertaken phase 2 and 3 trials to compare ZX-7101A in Chinese adult patients with uncomplicated influenza, focusing on both safety and efficacy. The study officially began on September 17, 2022, and is slated for completion by June 30, 2024.

Side effects associated with anti-viral drugs for influenza are generally mild and treatable, including symptoms such as nausea and vomiting. However, some anti-viral drugs can lead to bronchospasm and diarrhea, and it's essential to consider the specific safety profiles of these medications. Pregnant women are advised to opt for oral oseltamivir, as other drugs like Baloxavir pose severe complications in pregnancy and breastfeeding due to a lack of safety data. Zanamivir is an approved early flu treatment for individuals aged seven and older.

Influenza Therapeutics Market Segment Analysis

The global influenza therapeutics market segments are categorized based on disease type, therapeutics, route of administration, end-user, and region. Among these segments, vaccines are the most prominent, accounting for approximately 52.3% of the market share. Vaccines offer effective long-term protection against influenza compared to drugs, with mRNA vaccines gaining significance for their precision and rapid action. Leading vaccine manufacturers, including Pfizer and Moderna, are actively working on the development and launch of mRNA vaccines for influenza.

Pfizer Inc. initiated a phase 3 clinical trial in September 2022 to evaluate the efficacy, tolerability, and immunogenicity of quadrivalent modified RNA (modRNA) influenza vaccine. In February 2023, Moderna commenced a phase 3 clinical trial to assess the safety and efficacy of mRNA-1010, a seasonal influenza vaccine candidate.

Global Influenza Therapeutics Market Geographical Share

In 2022, North America secured the lion's share of the global influenza therapeutics market, accounting for approximately 41.2%. This dominance is attributed to the presence of major vaccine manufacturers such as Pfizer and Moderna, coupled with the escalating prevalence of influenza in the United States and Canada. In North America, influenza affects nearly 8% of the population annually, and WHO reports an estimated 650,000 influenza-related deaths worldwide, with over 90% occurring in adults aged at least 65. Canada's annual report on seasonal influenza reveals that during the 2021-2022 season, 16,126 laboratory-confirmed influenza cases were reported out of 751,900 total laboratory tests, with seniors (65 and older) representing nearly 71% of affected individuals.

Relevant Reports:

Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market 

Chronic Bronchitis Treatment Market

Hypoxia Treatment Market 

Breathing Disorder Treatment Market

Pneumoconiosis Treatment 

Interstitial lung disease (ILD) Market

About Us-

DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us -

Name: Sai k 

Designation: Sales & Senior Business Consultant

Email: info@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com